1. Search Result
Search Result
Results for "

P-53

" in MedChemExpress (MCE) Product Catalog:

292

Inhibitors & Agonists

6

Screening Libraries

1

Biochemical Assay Reagents

23

Peptides

29

Natural
Products

18

Recombinant Proteins

10

Isotope-Labeled Compounds

16

Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148404

    MDM-2/p53 Cancer
    p53 Activator 5 (compound 134A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 5 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 5 shows anti-tumor activity . p53 Activator 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>p53</em> Activator 5
  • HY-111990

    P-53

    Others Cardiovascular Disease
    Tetrofosmin is a drug used in nuclear medicine cardiac imaging .
    Tetrofosmin
  • HY-P5343

    p53 Consensus binding sequence

    MDM-2/p53 Others
    p53 CBS (p53 Consensus binding sequence) is a biological active peptide. (p53 consensus DNA binding site)
    <em>p53</em> CBS
  • HY-P1755

    MDM-2/p53 Cancer
    p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain .
    <em>p53</em> (17-26)
  • HY-158151

    MDM-2/p53 Cancer
    p53 Activator 12 (compound 510B) is a potent p53 activator. p53 Activator 12 binds to mutant p53 and restores the ability of the p53 mutant to bind DNA .
    <em>p53</em> Activator 12
  • HY-148402

    MDM-2/p53 Cancer
    p53 Activator 3 (compound 87A) is a potent p53 activator with a SC150 value of <0.05 mM. p53 Activator 3 can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA. p53 Activator 3 shows anti-tumor activity . p53 Activator 3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>p53</em> Activator 3
  • HY-160450

    MDM-2/p53 Cancer
    p53 Activator 11 (compound A-1) is a potent p53 activator with an EC50 value of 0.478 µM for p53 (Y220C). p53 Activator 11 has the potential for the research of cancer .
    <em>p53</em> Activator 11
  • HY-148416

    MDM-2/p53 Cancer
    p53 Activator 7 is a p53 mutation Y220C (MDM-2/p53) activator with an EC50 of 104 nM. p53 Activator 7 can bind to p53 mutant and restore its ability to bind DNA (WO2022213975A1; Example B-1) . p53 Activator 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>p53</em> Activator 7
  • HY-160449

    MDM-2/p53 Cancer
    p53 Activator 10 (Example C-2) is a compound that targets the y220c mutant of p53. p53 Activator 10 activation is involved in the downstream effects of tumor suppression .
    <em>p53</em> Activator 10
  • HY-146095

    MDM-2/p53 DNA/RNA Synthesis Apoptosis Cancer
    p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of p53, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.p53 Activator 2 induce apoptosis and significantly down-regulates the anti-apoptosis proteins Bcl-2, Bcl-xL and the levels of cyclin B1.p53 Activator 2 has anti-proliferation activity against MGC-803 cells, with an IC50 of 1.73 µM. p53 Activator 2 displays potent anticancer efficiency against MGC-803 xenograft tumors models .
    <em>p53</em> Activator 2
  • HY-156919

    MDM-2/p53 Cancer
    p53 Activator 8 (compound 5) is a p53 activator. p53 Activator 8 has potent anti-proliferative activity against MCF7 breast cancer cell lines with an IC 50 value of 0.5 μM .
    <em>p53</em> Activator 8
  • HY-160448

    Others Cancer
    p53 Activator 9 (example D-4) is a p53 activator with EC50 of 1.699μM .
    <em>p53</em> Activator 9
  • HY-70027A

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and MDM2 proteins-interaction-inhibitor dihydrochloride
  • HY-P1755F

    MDM-2/p53 Others
    p53 (17-26), FITC labeled is a biological active peptide.
    <em>p53</em> (17-26), FITC labeled
  • HY-70027

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and MDM2 proteins-interaction-inhibitor (chiral)
  • HY-70028

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.
    <em>p53</em> and MDM2 proteins-interaction-inhibitor (racemic)
  • HY-122578

    MDM-2/p53 Cancer
    P53R3 is a potent p53 reactivator and restores sequence-specific DNA binding of p53 hot spot mutants, including p53 R175H, p53 R248W and p53 R273H. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1. P53R3 enhances the recruitment of wild-type p53 and p53 M237I to several target gene promoters. P53R3 strongly enhances the mRNA, total protein and cell surface expression of the death receptor death receptor 5 (DR5). P53R3 is used for cancer research .
    <em>P53</em>R3
  • HY-145907

    MDM-2/p53 Cancer
    p53-HDM2-IN-1 is a potent inhibitor of p53-HDM2 protein-protein interaction, with an IC50 of 0.103 μM. p53-HDM2-IN-1 can be used for the research of cancer .
    <em>p53</em>-HDM2-IN-1
  • HY-W340839

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    p53-MDM2-IN-1 (Example 30) is an inhibitor of p53-MDM2/X protein interaction with an Ki value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .
    <em>p53</em>-MDM2-IN-1
  • HY-116052

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
    <em>p53</em>-MDM2-IN-2
  • HY-121893

    MDM-2/p53 NF-κB Cancer
    p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
    <em>p53</em>-MDM2-IN-3
  • HY-145759

    MDM-2/p53 Cancer
    Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
    Mutant <em>p53</em> modulator-1
  • HY-148833

    MDM-2/p53 Cancer
    MDM2-p53-IN-16 is a MDM2-p53 complex inhibitor with an IC50 value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .
    MDM2-<em>p53</em>-IN-16
  • HY-151172

    MDM-2/p53 Apoptosis Cancer
    MDM2-p53-IN-15 is a MDM2-p53 inhibitor with an IC50 value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .
    MDM2-<em>p53</em>-IN-15
  • HY-151171

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-3 is a MDM2/4-p53 protein-protein interactions (PPIs) inhibitor (IC50s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .
    MDM2/4-<em>p53</em>-IN-3
  • HY-151169

    MDM-2/p53 Cancer
    MDM2/4-p53-IN-1 is a potent MDM2-p53 and MDM4-p53 inhibitor with IC50 values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .
    MDM2/4-<em>p53</em>-IN-1
  • HY-151170

    MDM-2/p53 Apoptosis Cancer
    MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/ MDM4 inhibitor and p53 activator with the IC50 values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .
    MDM2/4-<em>p53</em>-IN-2
  • HY-161039

    MDM-2/p53 Cancer
    MDM2-p53-IN-18 (Compd A-7b) is a MDM2-p53 interaction inhibitor .
    MDM2-<em>p53</em>-IN-18
  • HY-161041

    MDM-2/p53 Cancer
    MDM2-p53-IN-20 (Compd B-11j) is a synthetic MDM2-p53 interaction inhibitor that play an important role in cancer .
    MDM2-<em>p53</em>-IN-20
  • HY-161040

    Others Cancer
    MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the MDM2-p53 interaction with anticancer activity .
    MDM2-<em>p53</em>-IN-19
  • HY-145900

    MDM-2/p53 Cancer
    S100A2-p53-IN-1 (compound 51) is a S100A2-p53 interactions inhibitor. S100A2 is a Ca 2+ binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer. S100A2-p53-IN-1 can inhibit the growth of the MiaPaCa-2 pancreatic cancer cell line (GI 50 of 1.2-3.4 μM) .
    S100A2-<em>p53</em>-IN-1
  • HY-P4210

    ALRN-6924; MP-4897

    MDM-2/p53 Cancer
    Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .
    Sulanemadlin
  • HY-156967

    MDM-2/p53 Cancer
    BAY 1892005 is a regulator of p53 protein and acts on p53 condensates without causing mutant p53 reactivation .
    BAY 1892005
  • HY-155974

    MDM-2/p53 Cancer
    MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .
    MeOIstPyrd
  • HY-18343A

    MDM-2/p53 Cancer
    CP-31398 dihydrochloride stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53 .
    CP-31398 dihydrochloride
  • HY-120086

    MDM-2/p53 E1/E2/E3 Enzyme Cancer
    RO-5963 is a dual p53-MDM2 and p53-MDMX inhibitor with IC50s of ~17 nM and ~24 nM, respectively .
    RO-5963
  • HY-144105

    MDM-2/p53 Cancer
    NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .
    NSC405640
  • HY-108636

    MDM-2/p53 Cancer
    RETRA is a mutant p53-dependent activator of p73 that suppresses mutant p53-bearing cancer cells. RETRA increases the expression level of p73, and a release of p73 from the blocking complex with mutant p53, which produces tumor-suppressor effects .
    RETRA
  • HY-P0121
    ReACp53
    2 Publications Verification

    MDM-2/p53 Cancer
    ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
    ReACp<em>53</em>
  • HY-19726
    NSC59984
    1 Publications Verification

    MDM-2/p53 Cancer
    NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling .
    NSC59984
  • HY-120373

    MDM-2/p53 Cancer
    MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines .
    MB710
  • HY-141584

    MDM-2/p53 Cancer
    ATSP-7041, a selective dual peptide inhibitor of MDM2 and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .
    ATSP-7041
  • HY-148408

    Sirtuin Cancer
    SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers .
    SIRT2-IN-11
  • HY-123544

    MDM-2/p53 Cancer
    RDR03871 (compound 2) is a potent dual MDM2/MDM4 inhibitor with IC50 values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .
    RDR03871
  • HY-A0280

    Benzylhexamethylenetetramine bromide

    MDM-2/p53 FAK Cancer
    Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator with anticancer effects. Roslin 2 bromide binds FAK, disrupts the binding of FAK and p53 .
    Roslin 2 bromide
  • HY-108639

    NSC 19630

    MDM-2/p53 Apoptosis Cancer
    MIRA-1 is a maleimide analogue. MIRA-1 can induce apoptosis in mutant p53 cells via restoration of p53-dependent transcriptional transactivation. MIRA-1 has anticancer activity .
    MIRA-1
  • HY-110088
    SCH529074
    1 Publications Verification

    MDM-2/p53 Cancer
    SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
    SCH529074
  • HY-142913

    Apoptosis Cancer
    ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.
    ABL-L
  • HY-117280

    MDM-2/p53 Cancer
    GN25 is a specific p53-Snail binding inhibitor with antitumor effects .
    GN25
  • HY-P10286

    MDM-2/p53 Cancer
    Phage-derived 12/1 peptide exhibits antitumor activity by targeting MDM2 and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC50 of 0.15 and 1.25 μM .
    Phage-derived 12/1 peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: